Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioharvest Sciences Inc CNVCF


Primary Symbol: C.BHSC

BioHarvest Sciences Inc. is a Canada-based biotechnology company. The Company offers Botanical Synthesis, its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. The Company is leveraging its Botanical Synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. The Company operates through two segments: Nutraceuticals and Pharmaceuticals. The Company offers a polyphenol/antioxidant superfruit product called VINIA, which is a red grape powder that supplies the benefits of red wine consumption but without the sugar, calories and alcohol found in wine.


CSE:BHSC - Post by User

Post by Betteryear2on Apr 06, 2022 1:45pm
181 Views
Post# 34581304

Bioharvest Sciences Inc. Reports Strong Q1 2022 Results

Bioharvest Sciences Inc. Reports Strong Q1 2022 Results
  • VINIA® sales orders grew 112% compared to Q1 2021 to reach USD 787k
  • Reiterating guidance for year-on-year sales orders growth of 2.5-3.5X to reach USD 5M - 7M
  • Started the transition of VINIA® production at new 20 tons/year facility enabling the scaling of VINIA® sales and conversion of current 2 tons/year facility to Cannabis
  • Produced a unique Cannabis composition in large industrial scale Bioreactors enabling the commercialization and sales of Cannabis products in H2 2022

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 6, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE:8MV) ("BioHarvest" or "the Company") today announced Q1 2022 sales of its flagship VINIA® product reached USD 787k, representing 112% growth compared to the same quarter of last year.


<< Previous
Bullboard Posts
Next >>